According to the sources provided, Enhertu is a cancer drug that is expected to experience growth in 2024. Enhertu is an antibody-drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo. It is used to treat patients with HER2-positive breast cancer that has spread to other parts of the body and has not responded to other treatments.
One source, Drug Patent Watch, provides information on the patent status of Enhertu. It indicates that the patent for Enhertu is set to expire in 2039, which suggests that the drug will continue to be available and generate revenue for AstraZeneca and Daiichi Sankyo in the coming years [1].
Another source, CNBC, mentions that there is renewed interest in ADCs, like Enhertu, in the field of cancer treatment. ADCs are a type of targeted therapy that combines an antibody with a chemotherapy drug. They are designed to deliver the chemotherapy drug directly to cancer cells, minimizing damage to healthy cells. The article states that the market for ADCs is expected to grow in 2024, and Enhertu is likely to benefit from this trend [2].
Additionally, Morningstar provides insights into AstraZeneca's overall performance and growth prospects. The article mentions that AstraZeneca has a broad-based portfolio that supports solid gains. While the article does not specifically mention Enhertu, it suggests that AstraZeneca's diverse product offerings contribute to its growth potential. This implies that Enhertu, as part of AstraZeneca's portfolio, may contribute to the company's growth in 2024 [3].
In summary, based on the provided sources, Enhertu is projected to grow in 2024. The drug's patent is set to expire in 2039, indicating that it will continue to generate revenue for AstraZeneca and Daiichi Sankyo. The renewed interest in ADCs, like Enhertu, in the field of cancer treatment is expected to drive the growth of the market for these drugs in 2024. AstraZeneca's broad-based portfolio, which includes Enhertu, also supports its potential for growth in the coming years.
Sources:
[1] Drug Patent Watch: https://www.drugpatentwatch.com/p/biologics/tradename/ENHERTU
[2] CNBC: https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html
[3] Morningstar: https://www.morningstar.com/stocks/astrazeneca-earnings-broad-based-portfolio-supports-solid-gains-deceleration-expected